EGFR基因在头颈部鳞状细胞癌中表达及临床应用的研究进展
Research Progress on the Expression and Clinical Application of EGFR Gene in Head and Neck Squamous Cell Carcinoma
DOI: 10.12677/ACM.2023.13122716, PDF,   
作者: 艾力非热·帕尔哈提:新疆医科大学第三临床医学院,新疆 乌鲁木齐;阿力比亚提·艾尼*:新疆医科大学附属肿瘤医院头颈外科,新疆 乌鲁木齐
关键词: 表皮生长因子受体头颈部鳞状细胞癌靶向治疗Epidermal Growth Factor Receptor (EGFR) Head and Neck Squamous Cell Carcinoma (HNSCC) Targeted Therapy
摘要: 头颈部肿瘤目前是世界第六大肿瘤。超过一半的头颈部肿瘤患者在首次诊断时已经是晚期。多年来,人们一直致力于研究头颈部肿瘤患者的治疗方法,但晚期患者仍然有较高的死亡率。近年来,研究发现表皮生长因子受体(EGFR)在许多恶性肿瘤中的高表达与肿瘤细胞增殖和转移密切相关,而EGFR在头颈部鳞状细胞癌(HNSCC)中也呈现高表达,因此EGFR基因在头颈部鳞癌中表达的研究和靶向治疗成为了热点。尽管许多相关临床试验显示出良好的前景,但在研究内容上比较局限,缺乏大量的III期临床试验数据加以支持。因此,本文主要通过探讨EGFR基因在头颈部鳞癌中的临床意义及研究现状,总结EGFR靶向治疗的研究进展,来提出未来的研究方向,为HNSCC的治疗提供更多的理论依据。
Abstract: Head and neck tumors are currently the sixth largest tumor in the world. More than half of patients with head and neck tumors are already in advanced stages at the initial diagnosis. For many years, people have been striving to find treatment methods for patients with head and neck tumors, but the mortality rate of advanced cases is still high. In recent years, studies have shown that the high expression of epidermal growth factor receptor (EGFR) in many malignant tumors is closely related to tumor cell proliferation and metastasis, and EGFR also exhibits high expression in head and neck squamous cell carcinoma (HNSCC). Therefore, the study of EGFR gene expression and targeted therapy in head and neck squamous cell carcinoma has become a hot topic. Although many related clinical trials have shown good prospects, the research content is relatively limited, and the data from phase three clinical trials is insufficient to support it. Therefore, this article explores the clini-cal importance and current research status of EGFR gene in head and neck epidermal cancer, sum-marizes the research progress of EGFR targeted therapy, and provides suggestions for future re-search directions, in order to provide additional theoretical basis for the treatment of HNSCC.
文章引用:艾力非热·帕尔哈提, 阿力比亚提·艾尼. EGFR基因在头颈部鳞状细胞癌中表达及临床应用的研究进展[J]. 临床医学进展, 2023, 13(12): 19295-19302. https://doi.org/10.12677/ACM.2023.13122716

参考文献

[1] Parkin, D.M. (2005) Global Cancer Statistics. CA: A Cancer Journal for Clinicians, 55, 74-108. [Google Scholar] [CrossRef] [PubMed]
[2] 马玲玲. 头颈部鳞癌HPV感染与p16、EGFR表达的关系及预后关系的研究[D]: [硕士学位论文]. 乌鲁木齐: 新疆医科大学, 2013.
[3] 冯守昊, 嵇庆海, 王玉龙. 表皮生长因子受体靶向治疗在头颈部鳞癌中的研究现状[J]. 中国癌症杂志中国癌症杂志, 2012, 22(12): 934-941.
[4] 顾倩平, 孟箭, 孟庆飞, 张杰, 李志萍. 尼妥珠单抗联合多西他赛-顺铂-氟尿嘧啶治疗晚期口腔癌的短期疗效观察[J]. 国际口腔医学杂志, 2011, 38(6): 652-655.
[5] 刘芬. 基于炮制原理的麸炒苍术药效及作用机制研究[D]: [博士学位论文]. 武汉: 湖北中医药大学, 2018.
[6] 张丹丹, 姚立. 京尼平苷通过抑制EGFR/PI3K/AKT通路和Ca2+通道减轻CCI大鼠的神经性疼痛[D]: [硕士学位论文]. 杭州: 浙江中医药大学, 2023.
[7] 伦立鑫, 钟振滨, 赵新宇, 等. 抗EGFR治疗在头颈部鳞癌中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(3): 276-280.
[8] Falls, D.L. (2003) Neuregulins: Functions, Forms, Signalings Strategies. Experimental Cell Research, 284, 14-30. [Google Scholar] [CrossRef
[9] Bonner, J.A., Harari, P.M., Giralt, J., et al. (2006) Radio-therapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. The New England Journal of Medicine, 354, 567-579. [Google Scholar] [CrossRef
[10] Bonner, J.A., Harari, P.M., Giralt, J., et al. (2010) Ra-diotherapy plus Cetuximab for Locoregionally Advanced Head and Neck Cancer: 5-Year Survival Data from a Phase 3 Randomised Trial, and Relation between Cetuximab-Induced Rash and Survival. The Lancet Oncology, 11, 21-28. [Google Scholar] [CrossRef
[11] Burtness, B., Goldwasser, M.A., Flood, W., et al. (2005) Phase Ⅲ Randomized Trial of Cisplatin plus Placebo Compared with Cisplatin plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study. Journal of Clinical Oncology, 23, 8646-8654. [Google Scholar] [CrossRef
[12] Vermorken, J.B., Mesia, R., Rivera, F., et al. (2008) Platinum Based Chemotherapy plus Cetuximab in Head and Neck Cancer. The New England Journal of Medicine, 359, 1116-1127. [Google Scholar] [CrossRef
[13] Pfister, D.G., Su, Y.B., Kraus, D.H., et al. (2006) Concurrent Etuximab, Cisplatin, and Concomitant Boost Radiotherapy for Locoregionally Advanced, Squamous Cell Head and Neck Cancer: A Pilot Phase II Study of a New Combined-Modality Paradigm. Journal of Clinical Oncology, 24, 1072-1078. [Google Scholar] [CrossRef
[14] Wirth, L.J., Allen, A.M., Posner, M.R., et al. (2010) Phase I Dosefinding Study of Paclitaxel with Panitumumab, Carboplatin and Ntensity-Modulated Radiotherapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck. Annals of Oncology, 21, 342-347. [Google Scholar] [CrossRef] [PubMed]
[15] Rischin, D., Spigel, D.R., Adkins, D., et al. (2010) Panitumumab (PMAB) Regimen in Second-Line Onotherapy (PRISM) in Patients (PTS) with Recurrent (R) or Metastatic (M) Squa-mous Cell Carcinoma of the Head and Neck (HNSCC): Interim Safety Analysis. Annals of Oncology, 21, Article 323.
[16] Vermorken, J.B., Stohlmacher, J., Davidenko, I., et al. (2010) Primary Efficacy and Safety Results of SPECTRUM, a Phase 3 Trial in Patients (PTS) with Recurrent and/or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (HNSCC) Receiving Chemotherapy with or without Panitumumab (PMAB). Annals of Oncology, 21, Article LBA26.
[17] 王亚琛, 郑旸, 杨月美, 等. 尼妥珠单抗与TPF的联合运用在头颈鳞癌中治疗效果的初步分析[J]. 口腔医学, 2023, 43(4): 312-316.
[18] Rodríguez, M.O., Rivero, T.C., Del-Castillo, B.R., et al. (2010) Nimotuzumab plus Radiotherapy for Unresectable Squamous-Cell Carcinoma of the Head and Neck. Cancer Biology & Therapy, 9, 343-349. [Google Scholar] [CrossRef] [PubMed]
[19] 王红, 吴云腾, 马旭辉, 等. EGFR单抗联合化疗治疗245例晚期头颈鳞癌疗效分析[J]. 中国口腔颌面外科杂志, 2019, 17(2): 129-133.
[20] 郭伟, 孙沫逸, 冉炜, 等. 尼妥珠单克隆抗体注射液治疗口腔颌面-头颈部鳞癌专家共识[J]. 实用口腔医学杂志, 2021, 37(4): 445-450.
[21] Cohen, E.E.W., Rosen, F., Stadler, W.M., et al. (2003) Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. Journal of Clinical Oncology, 21, 1980-1987. [Google Scholar] [CrossRef
[22] Cohen, E.E.W., Kane, M.A., List, M.A., et al. (2005) Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 11, 8418-8424. [Google Scholar] [CrossRef
[23] Hainsworth, J.D., Spigel, D.R., Burris, H.A., et al. (2009) Neoadjuvant Chemotherapy/Gefitinib Followed by Concurrent Chemotherapy/Radiation Therapy/Gefitinib for Patients with Locally Advanced Squamous Carcinoma of the Head and Neck. Cancer, 115, 2138-2146. [Google Scholar] [CrossRef] [PubMed]
[24] Siu, L.L., Soulieres, D., Chen, E.X., et al. (2007) Phase I/II Trial of Erlo-tinib and Cisplatin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group Study. Journal of Clinical Oncology, 25, 2178-2183. [Google Scholar] [CrossRef
[25] Herchenhorn, D., Dias, F.L., Viegas, C.M., et al. (2010) Phase I/II Study of Erlotinib Combined with Cisplatin and Radiotherapy in Patients with Locally Advanced Squamous Cell Carci-noma of the Head and Neck. International Journal of Radiation Oncology, Biology, Physics, 78, 696-702. [Google Scholar] [CrossRef] [PubMed]
[26] Kao, J., Genden, E.M., Chen, C.T., et al. (2011) Phase 1 Trial of Concurrent Erlotinib, Celecoxib, and Reirradiation for Recurrent Head and Neck Cancer. Cancer, 117, 3173- 3181. [Google Scholar] [CrossRef] [PubMed]
[27] Gilbert, J., Rudek, M.A., Higgins, M.J., et al. (2012) A Phase I Trial of Erlotinib and Concurrent Chemoradiotherapy for Stage III and IV (M0) Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 18, 1735-1742. [Google Scholar] [CrossRef
[28] Verma, J., Dhingra, V., Srivastava, S., et al. (2018) Evalua-tion of Epidermal Growth Factor Receptor Expression by a New Scoring System in Head-and-Neck Squamous Cell Car-cinoma and Its Association with Various Pathological Prognostic Factors. Journal of Oral and Maxillofacial Pathology, 22, 11-17. [Google Scholar] [CrossRef
[29] 陈晓钟, 金祁峰. 免疫检查点抑制剂在头颈部鳞癌治疗中的应用研究进展[J]. 浙江医学, 2023, 45(10): 1009-1012, 1018.
[30] Napolitano, S., Matrone, N., Muddassir, A.L., Martini, G., Sorokin, A., De Falco, V., Giunta, E.F., Ciardiello, D., Martinelli, E., Belli, V., Furia, M., Kopetz, S., Mor-gillo, F., Ciardiello, F. and Troiani, T. (2019) Triple Blockade of EGFR, MEK and PD-L1 Has Antitumor Activity in Colorectal Cancer Models with Constitutive Activation of MAPK Signaling and PD-L1 Overexpression. Journal of Ex-perimental & Clinical Cancer Research, 38, Article No. 492. [Google Scholar] [CrossRef] [PubMed]
[31] Zhang, J., Dang, F., Ren, J. and Wei, W. (2018) Biochemical As-pects of PD-L1 Regulation in Cancer Immunotherapy. Trends in Biochemical Sciences, 43, 1014-1032. [Google Scholar] [CrossRef] [PubMed]